RGNT REGENTIS BIOMATERIALS LTD.
Executive Summary
Regentis Biomaterials Ltd. filed Amendment No. 1 to its F-1 registration statement solely to update Exhibit 23.1 (consent of independent auditor) and the exhibit index. The prospectus (Part I) is unchanged. The company is proceeding with a firm-commitment offering of 3,333,334 ordinary shares at an assumed price of $3.00 per share, with ThinkEquity LLC as underwriter. This is a routine administrative amendment that does not alter the offering terms or business disclosure.
Key Financial Metrics
Actionable Insight
This is a purely administrative filing with no change to the offering terms. Monitor for the final prospectus (424B) which will set the actual offering price and confirm the effective date. The stock's $7M market cap and assumed $3.00 offering price imply significant dilution — watch for pricing updates and investor demand signals.
Key Facts
- Amendment No. 1 to F-1 filed solely to update Exhibit 23.1 (auditor consent) and exhibit index; Part I prospectus unchanged
- Firm-commitment offering of 3,333,334 ordinary shares at assumed $3.00/share (based on April 28, 2026 closing price)
- Underwriter: ThinkEquity LLC; 45-day option to purchase additional shares (amount not specified)
- Company is an Israeli emerging growth company and foreign private issuer; shares trade on NYSE American under RGNT
- Prior F-1 filed May 1, 2026; this amendment does not modify offering terms
Financial Impact
Offering size: 3,333,334 shares at assumed $3.00/share = approximately $10M gross proceeds before underwriting discounts and expenses
Risk Factors
- Dilution risk: offering of 3.33M shares against current market cap of $7M implies substantial shareholder dilution
- Execution risk: small-cap Israeli biotech IPO with ThinkEquity as sole underwriter may face pricing or demand challenges
- Pre-revenue company with no disclosed revenue or profitability in filing documents
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001213900-26-066555 |
| Document: ea029406901ex23-1.htm | 0001213900-26-066555 |
| Document: 0001213900-26-066555-index-headers.html | 0001213900-26-066555 |
| Document: 0001213900-26-066555-index.html | 0001213900-26-066555 |
| Document: 0001213900-26-066555.txt | 0001213900-26-066555 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
5d ago
|
F-1/A
| $2.70 awaiting T+20 | awaiting T+20 | — | $1.50 (−44.44%) |
|
Jun 8, 2026
6d ago
|
6-K
| $1.45 awaiting T+20 | awaiting T+20 | — | $1.50 (+3.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access